Baxter International Inc. recently alerted customers to significant safety issues with its Novum LVP infusion device, which controls the delivery of intravenous fluids to patients. The company sent two warning letters, first on April 24, 2025, disclosing underinfusion risks and one linked serious injury, and again on July 14, 2025, revealing both underinfusion and overinfusion risks. The latest communication reported 79 serious injuries and two patient deaths associated with the device. Despite these incidents, Baxter did not instruct hospitals to remove the Novum LVP from service, instead providing guidance on correction steps while continuing its use. The situation has led to a securities class action lawsuit concerning disclosures made during the period from February 23, 2022, to July 30, 2025.